🧬 RNAi Technology: Revolutionizing Gene Silencing
RNA interference (RNAi) is a biological process where RNA molecules inhibit gene expression by neutralizing targeted mRNA molecules. Since its discovery, RNAi has become a powerful tool for genetic research and therapy.
🧪 What Is RNAi?
RNAi involves:
Small interfering RNA (siRNA) or
MicroRNA (miRNA)binding to complementary mRNA sequences, leading to their degradation or suppression, effectively silencing specific genes.
💡 Applications
Therapeutics
Treating diseases by silencing harmful genes
Applications in cancer, viral infections, neurodegenerative disorders, and rare genetic diseases
Example: Patisiran, the first FDA-approved RNAi drug (for hereditary ATTR amyloidosis)
Drug Discovery
High-throughput screening to identify gene targets
Agricultural Biotechnology
Pest-resistant crops through gene silencing
Viral protection in plants
Functional Genomics
Studying gene function by "turning off" specific genes
📈 Market Outlook
2024 Market Size Estimate: ~$1.5–2 billion
Projected CAGR (2024–2032): 12–15%
Growth Factors:
Increase in rare disease research
Rise in precision medicine
Advancements in delivery systems like lipid nanoparticles (LNPs)
🔬 Challenges
⚠️ Delivery mechanisms: Ensuring RNA molecules reach target tissues without degradation
🧠 Off-target effects and safety concerns
💰 High production costs
🏢 Key Companies
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals (acquired by Novo Nordisk)
Silence Therapeutics
Sirnaomics